Tela Bio Inc (TELA) Stock Price, Quote & News

Company Profile

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex...

Industry: Medical Devices

Sector: Healthcare

Phone: 484 320 2930

Website: www.telabio.com

Address:

1 Great Valley Parkway, Suite 24, Malvern, United States

CandleSnipe Sep. 20 at 8:39 PM

$TELA Operating costs targeted $17M / 18%…

0 · Reply

Yingtrader7 Sep. 17 at 2:08 PM

$NSYS great little $TELA putting us to shame.

0 · Reply

Knot2 Sep. 14 at 8:11 PM

$TELA

0 · Reply

ToadEsquireCapital Sep. 13 at 5:12 PM

$TELA buy at .7 sell at .9

0 · Reply

MingChoo Sep. 13 at 12:35 PM

$TELA Bulllish00

0 · Reply

et1000 Sep. 11 at 11:29 PM

Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $BUUU $JLHL $JILL $TELA SL

0 · Reply

OnlyFibs Sep. 7 at 8:43 PM

$TELA | TELA Bio, Inc. (Healthcare / Medical Devices & Technology 🏥🔬⚡) $TELA is compressing inside a falling wedge / descending channel on the 8H chart, bouncing directly off its $0.5011 macro 52-week low demand floor. The stock is holding near its $0.5400–$0.6700 volume profile support zone with RSI turning up from oversold conditions. Reclaiming $0.8500 opens a clear liquidity gap push back toward upper supply levels. Key Technical Levels: • Confirmation Trigger: $0.8500 🚀 • Pivot Support: $0.5400 🐂 • Overhead Target 1: $1.0700 🎯 • Overhead Target 2: $1.2800 💰 • Downside Risk Level: $0.5011 🐻 • Stop Loss: $0.4800 🔴 Flow & Market Bias: Structure: 8H Descending Wedge Compression / 52-Week Low Demand Floor Bounce Bias: Bullish above $0.5400 #TELA #optionsflow #stockmarket #technicalanalysis #swingtrading #hovdid

0 · Reply

Dr_Monkeybreath Sep. 1 at 1:39 PM

$TELA .80 is still cheap. new CEO means business. not sure what people are waiting for. 🤷‍♂️

0 · Reply

BioTuesdays Aug. 31 at 2:17 PM

$TELA has announced that Roberto Cuca, chief operating officer and chief financial officer (COO/CFO), will step down from the role effective today. https://biotuesdays.com/2026/08/31/tela-announces-coo-cfo-transition-and-cost-reduction/

0 · Reply

DonCorleone77 Aug. 31 at 1:10 PM

$EIX $SRE $TELA $PINS $AON PRE-MARKET MOVERS: Currently Higher After Earnings: - SAIC (SAIC) up 12.1% - BioLineRx (BLRX) up 5.0% - GameStop (GME) up 3.8% Currently Also Higher: - SLB (SLB) up 1.9% after signing an agreement to acquire Kelvion for $3.4B in cash Currently Higher Following Renewed Strikes in the Middle East: - Halliburton (HAL) up 2.7% - Chevron (CVX) up 2.3% - Valero (VLO) up 2.1% - Occidental (OXY) up 2.4% - Exxon Mobil (XOM) up 2.2% Currently Lower: - PG&E (PCG), Edison International (EIX) and Sempra Energy (SRE) down 18.9%, 19.9% and 3.6%, respectively, after KCRA reported California lawmakers are barring Governor Gavin Newsom from moving forward with his plan to prevent insurers in the state from recouping their losses from investor-owned utilities that cause a catastrophic wildfire - Tela Bio (TELA) down 4.0% after announcing that Roberto Cuca, COO and CFO, will step down from the role effective immediately - Pinterest (PINS) down 3.6% after disclosing that Julia Brau Donnelly, CFO, submitted her resignation to Pinterest to pursue another opportunity. - Aon plc (AON) down 1.8% after entering a definitive agreement to acquire USI from KKR (KKR) and other shareholders for a total purchase price of $17B

0 · Reply

TELA Bio Proxy statement: Proxy filing

Sep 4, 2026, 8:00 AM EDT - 17 days ago

TELA Bio Proxy statement: Proxy filing

2026-08-31T11:15:37.000Z - 21 days ago

Tela Bio COO, CFO Roberto Cuca steps down

Aug 31, 2026, 7:00 AM EDT - 21 days ago

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

2026-08-10T20:45:32.000Z - 6 weeks ago

Tela Bio reports Q2 EPS (20c), consensus (18c)

2026-08-10T20:45:28.000Z - 6 weeks ago

Tela Bio withdraws FY26 guidance

Aug 10, 2026, 4:30 PM EDT - 6 weeks ago

TELA Bio Earnings Call Transcript: Q2 2026

Aug 10, 2026, 4:30 PM EDT - 6 weeks ago

TELA Bio Earnings release: Q2 2026

Aug 10, 2026, 4:30 PM EDT - 6 weeks ago

TELA Bio Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 6 weeks ago

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-04T13:21:41.000Z - 6 weeks ago

Tela Bio appoints Heather Getz as CEO

BFLY

Aug 4, 2026, 7:00 AM EDT - 6 weeks ago

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

Jul 29, 2026, 4:05 PM EDT - 7 weeks ago

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Jul 20, 2026, 4:05 PM EDT - 2 months ago

TELA Bio to Announce Second Quarter 2026 Financial Results

May 12, 2026, 4:30 PM EDT - 4 months ago

TELA Bio Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

TELA Bio Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

TELA Bio Quarterly report: Q1 2026

May 12, 2026, 4:05 PM EDT - 4 months ago

TELA Bio Reports First Quarter 2026 Financial Results

Apr 30, 2026, 4:43 PM EDT - 4 months ago

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

Apr 30, 2026, 8:00 AM EDT - 4 months ago

TELA Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

TELA Bio Proxy statement: Proxy filing

Apr 21, 2026, 4:05 PM EDT - 5 months ago

TELA Bio to Announce First Quarter 2026 Financial Results

2026-03-27T09:45:34.000Z - 5 months ago

Tela Bio price target lowered to $3 from $5 at Citizens

2026-03-25T12:46:38.000Z - 6 months ago

Tela Bio price target lowered to $2 from $3 at Lake Street

2026-03-25T10:47:07.000Z - 6 months ago

Tela Bio price target lowered to $2 from $4 at Canaccord

2026-03-25T10:45:14.000Z - 6 months ago

Tela Bio price target lowered to $1 from $1.25 at Piper Sandler

Mar 24, 2026, 4:30 PM EDT - 6 months ago

TELA Bio Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 6 months ago

TELA Bio Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 6 months ago

TELA Bio Earnings release: Q4 2025

2026-03-24T20:18:38.000Z - 6 months ago

Tela Bio reports Q4 EPS (17c), consensus (18c)

2026-03-24T20:18:24.000Z - 6 months ago

Tela Bio sees Q1 revenue $18.5M, consensus $21.27M

Mar 24, 2026, 4:05 PM EDT - 6 months ago

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 10, 2026, 4:05 PM EDT - 6 months ago

TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results

2025-12-12T12:15:29.000Z - 9 months ago

Tela Bio files to sell 2M shares of common stock for holders

Dec 12, 2025, 7:00 AM EST - 9 months ago

TELA Bio Registration statement: Registration Filing

Dec 3, 2025, 2:30 PM EST - 9 months ago

TELA Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-01T13:45:43.000Z - 9 months ago

Tela Bio price target lowered to $3 from $6 at Lake Street

Nov 19, 2025, 8:30 AM EST - 10 months ago

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-11-18T11:15:46.000Z - 10 months ago

Tela Bio price target lowered to $4 from $7 at Canaccord

2025-11-14T11:51:53.000Z - 10 months ago

Tela Bio price target lowered to $1.25 from $2 at Piper Sandler

2025-11-14T10:55:56.000Z - 10 months ago

Tela Bio price target lowered to $5 from $7 at Citizens JMP

Nov 13, 2025, 4:30 PM EST - 10 months ago

TELA Bio Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

TELA Bio Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

TELA Bio Earnings release: Q3 2025

Nov 13, 2025, 4:21 PM EST - 10 months ago

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

2025-11-13T21:17:42.000Z - 10 months ago

Tela Bio reports Q3 EPS (19c), consensus (20c)

2025-11-13T21:17:31.000Z - 10 months ago

Tela Bio sees FY25 revenue up at least 16%

Nov 13, 2025, 4:01 PM EST - 10 months ago

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

Oct 9, 2025, 4:05 PM EDT - 11 months ago

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

Aug 13, 2025, 10:00 AM EDT - 1 year ago

TELA Bio Transcript: Canaccord Genuity’s 45th Annual Growth Conference

2025-08-11T20:30:41.000Z - 1 year ago

Tela Bio reports Q2 EPS (22c), consensus (19c)

2025-08-11T20:30:35.000Z - 1 year ago

Tela Bio backs FY25 revenue view $85M-$88M, consensus $86.05M

Aug 11, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings release: Q2 2025

Aug 11, 2025, 4:03 PM EDT - 1 year ago

TELA Bio Reports Second Quarter 2025 Financial Results

Aug 10, 2025, 6:00 PM EDT - 1 year ago

TELA Bio Slides: Investor Presentation

Jul 23, 2025, 4:03 PM EDT - 1 year ago

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 21, 2025, 4:03 PM EDT - 1 year ago

TELA Bio to Announce Second Quarter 2025 Financial Results

Jun 6, 2025, 4:05 PM EDT - 1 year ago

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 11:05 AM EDT - 1 year ago

TELA Bio Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 4:05 PM EDT - 1 year ago

TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair

Jun 2, 2025, 8:30 AM EDT - 1 year ago

TELA Bio Appoints Jeffrey Blizard as President

May 22, 2025, 4:05 PM EDT - 1 year ago

TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings release: Q1 2025

Apr 17, 2025, 4:05 PM EDT - 1 year ago

TELA Bio to Announce First Quarter 2025 Financial Results

Apr 17, 2025, 8:00 AM EDT - 1 year ago

TELA Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

TELA Bio Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

TELA Bio Proxy statement: Proxy Filing

Mar 20, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings Call Transcript: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Annual report: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

TELA Bio Earnings release: Q4 2024

Mar 20, 2025, 4:05 PM EDT - 1 year ago

TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

Dec 3, 2024, 12:00 PM EST - 1 year ago

TELA Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 1 year ago

TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference

Nov 7, 2024, 4:30 PM EST - 1 year ago

TELA Bio Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

TELA Bio Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

TELA Bio Earnings release: Q3 2024

Oct 24, 2024, 4:05 PM EDT - 1 year ago

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 23, 2024, 8:07 AM EDT - 1 year ago

TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Oct 22, 2024, 4:05 PM EDT - 1 year ago

TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Oct 17, 2024, 4:05 PM EDT - 1 year ago

TELA Bio to Announce Third Quarter 2024 Financial Results

Aug 14, 2024, 10:30 AM EDT - 2 years ago

TELA Bio Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 12, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings release: Q2 2024

Aug 12, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance

Jul 22, 2024, 4:05 PM EDT - 2 years ago

TELA Bio to Announce Second Quarter 2024 Financial Results

Jun 4, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Appoints Jeffrey Blizard to its Board of Directors

May 20, 2024, 4:03 PM EDT - 2 years ago

TELA Bio Appoints Greg Firestone as Chief Commercial Officer

May 9, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings release: Q1 2024

May 9, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 2 years ago

TELA Bio to Announce First Quarter 2024 Financial Results

Apr 18, 2024, 8:00 AM EDT - 2 years ago

TELA Bio Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

TELA Bio Proxy statement: Proxy Filing

Apr 15, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

Apr 8, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

Mar 21, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings Call Transcript: Q4 2023

Mar 21, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Annual report: Q4 2023

Mar 21, 2024, 4:30 PM EDT - 2 years ago

TELA Bio Earnings release: Q4 2023

Mar 21, 2024, 4:05 PM EDT - 2 years ago

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

Mar 21, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

Mar 20, 2024, 7:00 AM EDT - 2 years ago

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

Feb 29, 2024, 7:00 AM EST - 2 years ago

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

Dec 5, 2023, 7:00 AM EST - 2 years ago

TELA Bio to Take Part in Connecting the Dots

Nov 30, 2023, 11:00 AM EST - 2 years ago

TELA Bio Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 16, 2023, 7:00 AM EST - 2 years ago

TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 2 years ago

TELA Bio Registration statement: Registration Filing

Nov 9, 2023, 4:30 PM EST - 2 years ago

TELA Bio Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

TELA Bio Quarterly report: Q3 2023

Nov 9, 2023, 4:30 PM EST - 2 years ago

TELA Bio Earnings release: Q3 2023

Nov 9, 2023, 4:05 PM EST - 2 years ago

TELA Bio Reports Third Quarter 2023 Financial Results

Oct 26, 2023, 7:00 AM EDT - 2 years ago

TELA Bio to Announce Third Quarter 2023 Financial Results

Sep 18, 2023, 4:05 PM EDT - 3 years ago

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

Aug 16, 2023, 7:00 AM EDT - 3 years ago

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Aug 9, 2023, 4:30 PM EDT - 3 years ago

TELA Bio Earnings Call Transcript: Q2 2023

Aug 9, 2023, 4:30 PM EDT - 3 years ago

TELA Bio Quarterly report: Q2 2023

Aug 9, 2023, 4:30 PM EDT - 3 years ago

TELA Bio Earnings release: Q2 2023

Aug 9, 2023, 4:03 PM EDT - 3 years ago

TELA Bio Reports Second Quarter 2023 Financial Results

Jul 26, 2023, 7:00 AM EDT - 3 years ago

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

Jun 15, 2023, 7:00 AM EDT - 3 years ago

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

CandleSnipe Sep. 20 at 8:39 PM

$TELA Operating costs targeted $17M / 18%…

0 · Reply

Yingtrader7 Sep. 17 at 2:08 PM

$NSYS great little $TELA putting us to shame.

0 · Reply

Knot2 Sep. 14 at 8:11 PM

$TELA

0 · Reply

ToadEsquireCapital Sep. 13 at 5:12 PM

$TELA buy at .7 sell at .9

0 · Reply

MingChoo Sep. 13 at 12:35 PM

$TELA Bulllish00

0 · Reply

et1000 Sep. 11 at 11:29 PM

0 · Reply

OnlyFibs Sep. 7 at 8:43 PM

0 · Reply

Dr_Monkeybreath Sep. 1 at 1:39 PM

$TELA .80 is still cheap. new CEO means business. not sure what people are waiting for. 🤷‍♂️

0 · Reply

BioTuesdays Aug. 31 at 2:17 PM

0 · Reply

DonCorleone77 Aug. 31 at 1:10 PM

0 · Reply

prismmarketview Aug. 31 at 12:09 PM

$TELA TELA Bio combined COO/CFO Roberto Cuca departs effective immediately. Company simultaneously announces $17.0M (18%) annual opex reduction via ~20% headcount cut + streamlined external resources. Goal: extend cash runway into 2028 (Q2 cash was $30.4M). ~$1.5M one-time Q3 restructuring charge expected, mostly severance. Note: leadership exit + cost-cutting on the same day is a combo worth scrutinizing, not just reading as efficiency progress. https://prismmarketview.com/companies/tela-bio-inc/#news

0 · Reply

Dr_Monkeybreath Aug. 28 at 4:40 PM

$WHLR overnight flip💰ready to expand my position at $TELA 😎

0 · Reply

ToadEsquireCapital Aug. 26 at 4:03 AM

$TELA At this rate, reverse split gonna be needed to raise this above a dollar to avoid delisting.

0 · Reply

Dr_Monkeybreath Aug. 24 at 5:43 PM

$TELA what's with the volume surge??? this thing never trades 2m sideways. 🤔

0 · Reply

Dr_Monkeybreath Aug. 21 at 8:09 PM

$CAPS if you're looking for opportunities to make back some losses, $TELA under .70 might be worth a 👀.

0 · Reply

Dr_Monkeybreath Aug. 20 at 7:50 PM

$TELA don't mind being the only buyer. 27,650 @ .67. 😏

0 · Reply

Dr_Monkeybreath Aug. 18 at 2:13 PM

$TELA will double my position under .60. 🤝

0 · Reply

CEOBuysDisclosures Aug. 17 at 10:35 PM

$TELA CEO purchased 15,000 shares at $0.70 for a total of $10,467. Getz Heather C now owns 520,000 shares. https://ceo-buys.com

0 · Reply

ToadEsquireCapital Aug. 17 at 8:29 PM

$TELA buy or going to zero?

0 · Reply

Dr_Monkeybreath Aug. 14 at 8:01 PM

$TELA 20,000 @ .68. 😎

0 · Reply

Dr_Monkeybreath Aug. 14 at 4:07 PM

$TELA 15,000 @ .687. 😁

0 · Reply

Dr_Monkeybreath Aug. 14 at 2:29 PM

$TELA 12,000 🍽️

0 · Reply

Market Cap	56.43M
Revenue (ttm)	80.28M
Net Income (ttm)	-38.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48.37%
Debt to Equity Ratio	-3.53

Volume	213,600
Avg Vol	222,064
Day's Range	N/A - N/A
Shares Out	45.14M
Stochastic %K	90%
Beta	1.36
Analysts	Strong Sell
Price Target	$2.10